AACG vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 04, 2026

AACG

49.2
AI Score
VS
AACG Wins

XBIO

41.3
AI Score

Investment Advisor Scores

AACG

49score
Recommendation
HOLD

XBIO

41score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric AACG XBIO Winner
Revenue 38.34M 2.98M AACG
Net Income -6.87M -2.68M XBIO
Net Margin -17.9% -90.1% AACG
Operating Income -9.17M -2.83M XBIO
ROE -149.9% -36.2% XBIO
ROA -11.8% -32.1% AACG
Total Assets 58.39M 8.36M AACG
Cash 12.19M 7.88M AACG
Current Ratio 0.32 8.32 XBIO

Relative Price Performance (Last 90 Days)

AACG 1M: -13.5% · 3M: -23.1% XBIO 1M: -4.0% · 3M: -10.4%

Current Technical Phase

AACG

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 42

RSI (14): 41.7 · Price: $0.90

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.0 · Price: $2.66

Fundamentals Snapshot

Metric AACG XBIO
Market Cap
Forward P/E 15.4 -7.8
Trailing P/E
Revenue (TTM)
Revenue Growth -0.1% 0.4%
Gross Margin 0.5% 1.0%
Operating Margin 0.1% -0.6%
EPS -0.22 -1.19
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, AACG is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.